comparemela.com

Latest Breaking News On - Hmnc holding gmbh - Page 1 : comparemela.com

Investegate |HMNC Holding GmbH Announcements | HMNC Holding GmbH: HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression

Investegate announcements from HMNC Holding GmbH, HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression

Baden wübergSwitzerland generalSouth africaAnne donohoeSophia bashfordHans erikssonDevelco pharmaKetabon programBrain healthHolding gmbHmnc brain healthOral prolonged release ketamineTopline results expectedTreatment resistant depressionChief medical officerDepression rating scale

Investegate |HMNC Holding GmbH Announcements | HMNC Holding GmbH: HMNC Brain Health Raises EUR 14 3 million to Advance Precision Psychiatry Therapies

Investegate announcements from HMNC Holding GmbH, HMNC Brain Health Raises EUR 14.3 million to Advance Precision Psychiatry Therapies

Anne donohoeSophia bashfordWilhelm beierToni kroosMaximilian doeblerGuntard gutmannDevelco pharmaJosef ackermannWilhelm beier dermapharmAlexander schmidt europeCarsten maschmeyerHans kompernaHolding gmbHmnc brain health raisesDeutsche bankJahr group

Investegate |HMNC Holding GmbH Announcements | HMNC Holding GmbH: HMNC Brain Health to Participate in the H C Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond on June 27, 2022

Investegate announcements from HMNC Holding GmbH, HMNC Brain Health to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond on June 27, 2022

Anne donohoeSophia bashfordAlexander schmidt europeStrategic communicationsHmnc brain health toHolding gmbBrain healthMental health conferenceAnnual mental health conferenceMajor depressive disorderTreatment resistant depressionInvestegate announcementsInvestegate company announcementsHmnc holding gmbhLobenewswire and globenewswire

Investegate |HMNC Holding GmbH Announcements | HMNC Holding GmbH: First patient dosed in second Phase 2 add-on Ketamine Trial in Treatment-Resistant Depression (TRD)

Investegate announcements from HMNC Holding GmbH, First patient dosed in second Phase 2 add-on Ketamine Trial in Treatment-Resistant Depression (TRD)

South africaSwitzerland generalBaden wübergAnne donohoeSophia bashfordDevelco pharmaAlexander schmidt europeHans erikssonKetabon programHolding gmbBrain healthKetamine trialTreatment resistant depressionChief medical officerSwiss based develco pharmaDepression rating scale

First patient dosed in second Phase 2 add-on Ketamine Trial

Dosing has commenced in HMNC Brain Health and Develco Pharma’s Phase 2 oral prolonged-release Ketamine (KET01) Study The trial will assess the efficacy,.

South africaSwitzerland generalBaden wübergAnne donohoeSophia bashfordDevelco pharmaAlexander schmidt europeHans erikssonKetabon programHolding gmbBrain healthTreatment resistant depressionChief medical officerSwiss based develco pharmaDepression rating scaleMajor depressive disorder

vimarsana © 2020. All Rights Reserved.